Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVD-003 is an autologous therapy derived from adipose stem cells, which reverses severe bone deterioration and to achieve accelerated ossification, is being investigated as a single treatment to save limbs and restore mobility in patients with CPT.
Product Name : NVD-003
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVD-003, an autologous tissue engineered product generated from the patients’ own adipose stem cells, was applied in nine patients with bone non-union of the lower limb who had previously undergone several surgical procedures.
Product Name : NVD-003
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : NVD-003
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase I/IIa study was a six-month open-label trial. It evaluated the safety and efficacy of ALLOB in the treatment of delayed-union fractures of long bones.
Product Name : ALLOB
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : Allogeneic Osteoblastic Cell
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable